Advancing Antimicrobial Science: Targeting Biofilms and Drug-Resistant Pathogens

Breakthrough solutions tackling biofilms, antibiotic resistance, and chronic infections

At MHCombiotic, we are pioneering Combiotic™ technology, a cutting-edge antimicrobial platform designed to overcome the growing global crisis of antimicrobial resistance (AMR).

Through extensive research and collaborations with leading institutions, we have developed targeted solutions to combat wound and respiratory infections.

Mechanism of Action

Our comprehensive multi-OMICS studies, combined with probe-based assays, have shown that our plant-based agents target the bacterial cell membrane in the initial step. The bacterial cell membrane has a composition that is markedly different from eukaryotic cell membranes, explaining the agents’ selectivity and thus their safety as antibacterial agents. Moreover, these agents increase glutathione (GSH) levels in eukaryotic cells. GSH is a powerful antioxidant known for its anti-inflammatory properties, playing a crucial role in protecting cells from oxidative stress and reducing inflammation in the body. As a tripeptide composed of glutamine, cysteine, and glycine, GSH is vital for maintaining cellular health and immune function, acting like a shield for human cells. On the other hand, inorganic salts primarily affect four cellular processes of bacteria: sulfur homeostasis, reactive oxygen species response (by disrupting iron-sulfur (Fe–S) clusters), energy pathways, and the bacterial cell membrane.

Advancing Antimicrobial Solutions for Critical Infections

Innovative Pipeline

Medical Devices

Discovery

Validation

Biocompatibility

Approval

Commercialization

ComBatic™ Antimicrobial Wound Care

Therapeutics

Discovery

Pre-Clinical

Phase I

Phase II

Phase III

Combiotic™ for Respiratory Infection

Wound Care – Medical Device

Targeting Biofilms to Enhance Wound Healing and Infection Control

Disrupts biofilms and improves antimicrobial efficacy
Non-toxic with antioxidant properties to promote healing
Reduces infection recurrence and potential resistance

Biofilms are structured microbial communities that form on wound surfaces, delaying healing and increasing infection risk. Over 90% of chronic wounds, including diabetic foot ulcers, involve biofilms, leading to prolonged treatment, higher healthcare costs, and increased risk of amputation. Combiotic™ technology has been developed after screening 18,000+ formulations, demonstrating efficacy in biofilm disruption, infection control, and wound recovery acceleration while minimizing toxicity and antimicrobial resistance.

Respiratory – Therapeutics

Antimicrobial and Anti-Inflammatory Approach for Respiratory Infections

Antibacterial and antibiofilm properties targeting resistant pathogens
Anti-inflammatory and antioxidant effects to support lung health
Addresses high-risk patient populations prone to severe complications

Respiratory infections remain a leading cause of global mortality, disproportionately affecting infants, the elderly, and immunocompromised individuals. Combiotic™ technology is being investigated for its broad-spectrum antimicrobial properties, capable of inhibiting biofilm formation, bacterial proliferation, and inflammation. Its ability to mitigate oxidative stress and enhance antimicrobial potency offers potential therapeutic applications in managing drug-resistant respiratory infections.

Let’s Connect and Innovate Together

Have questions about our technology, research, or partnerships? We’d love to hear from you!